Is Mirabegron (Mirabeq) safe to use in a patient with hypertension, and what dosing and blood pressure monitoring are recommended?

Mirabegron Can Be Used in Patients with Controlled Hypertension, But Is Contraindicated in Severe Uncontrolled Hypertension

Mirabegron is safe to use in patients with well-controlled hypertension, but is absolutely contraindicated in those with severe uncontrolled hypertension (≥180/110 mmHg). For patients with controlled hypertension, initiate at standard dosing with regular blood pressure monitoring.

Key Contraindication

According to the 2023 European Association of Urology guidelines, mirabegron is contraindicated in patients with severe uncontrolled hypertension 1. This is defined as systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg 2.

Safety Profile in Controlled Hypertension

The evidence strongly supports mirabegron use in patients with controlled hypertension:

• Cardiovascular safety analysis of 13,396 patients showed no increased CV risk compared to placebo or antimuscarinics, with CV adverse events occurring in only 0.4-1.5% of mirabegron users versus 0.9% in placebo 3

• Real-world study of 46 hypertensive women with OAB demonstrated 73.6% symptom improvement, with only 6.5% (3 patients) experiencing blood pressure increases that resolved after stopping mirabegron 4

• Mirabegron is well tolerated in elderly patients and those with multiple comorbidities 1

Blood Pressure Effects and Monitoring

Expected BP Changes

• Most patients experience minimal BP changes: In a study of 263 OAB patients, systolic BP did not change significantly overall, though 20.2% had increases ≥10 mmHg 5

• Age is a risk factor: Elderly patients (≥65 years) were more likely to experience SBP increases (23.4% vs 7.4% in younger patients) 5

• Diastolic BP may actually decrease: Significant reductions in diastolic BP were observed in elderly patients (71.5 to 69.5 mmHg, p=0.012) 5

Monitoring Protocol

Implement the following BP monitoring schedule:

1. Baseline: Confirm BP is controlled (<140/90 mmHg per ISH 2020 guidelines 6)
2. First month: Check BP 2-4 weeks after initiation
3. Ongoing: Monthly BP checks for first 3 months, then every 3 months if stable 4, 5
4. Home monitoring: Consider home BP monitoring for early detection of worsening control 4

Dosing Recommendations

• Standard dosing applies: No dose adjustment needed for controlled hypertension
• Start at 25 mg daily in elderly or those with multiple comorbidities 1
• Titrate to 50 mg daily if needed and tolerated
• Discontinue immediately if BP rises to severe uncontrolled levels (≥180/110 mmHg)

Common Pitfalls to Avoid

1. Don't confuse "elevated BP" with "severe uncontrolled hypertension": Patients with BP 140-179/90-109 mmHg on treatment can use mirabegron with monitoring 1

2. Don't overlook baseline CV risk factors: History of arrhythmia, coronary artery disease, or stroke/TIA are more predictive of CV events than mirabegron use itself 3

3. Don't forget the most common adverse effects are NOT hypertension: UTIs, headache, and nasopharyngitis are more frequent than BP increases 1

4. Don't assume all BP increases are clinically significant: Meta-analysis showed no higher risk of hypertension with mirabegron versus antimuscarinics 7

When to Choose Alternative Therapy

Consider antimuscarinics instead if:

• BP is ≥180/110 mmHg (absolute contraindication)
• Patient has difficulty with regular BP monitoring
• Multiple failed attempts to control BP despite optimal antihypertensive therapy
• Patient experiences BP increase >10 mmHg on mirabegron despite dose adjustment

Antihypertensive Management Context

If initiating or adjusting antihypertensives while on mirabegron, follow standard hypertension guidelines:

• Target BP <140/90 mmHg for most patients 6
• Target <130/80 mmHg for high-risk patients (CVD, CKD, diabetes) 8, 9
• First-line agents: ACEi/ARB, thiazide-like diuretics, or long-acting dihydropyridine CCBs 8, 9